InnovaHealth Partners

Portfolio Company

OrthoSpace

OrthoSpace offers a simple to implant, biodegradable balloon that is revolutionizing the treatment massive rotator cuff tears. To date, over 11,000 patients have been treated by this minimally invasive procedure and the US pivotal trial is well underway.
Learn More

Portfolio Company

BioHorizons

BioHorizons is a global dental implant company with a highly-differentiated technology that prevents soft tissue migration and promotes osseointegration.

Learn More

Portfolio Company

Blue Belt

Blue Belt is one of three significantly commercialized orthopedic surgical robotics companies. It is now a part of Smith & Nephew.

Learn More

IH Interests

Richard B. Emmitt Joins InnovaHealth Partners as Senior Advisor

 

Learn More

IH Interests

OrthoSpace Announces the Publication of Positive InSpace™ Study

 

Learn More

Focus

InnovaHealth Partners is a New York City based investment firm concentrating on growth buyouts of late stage medical technology companies. Our focus is on the highest growth and largest sectors of the medical device industry.

We partner with exceptional management teams to build innovative, differentiated and high-growth medical device companies. Our investments address large unmet surgical needs on a global scale, meaningfully enhance patient outcomes and improve healthcare results on a sustainable basis.

With our expertise and relationships in major markets around the world, we identify later stage opportunities involving disruptive technologies. When combined with strong management, strategic insight and capital, the InnovaHealth portfolio companies unlock substantial value for all stakeholders.

Learn More

Strategy

InnovaHealth Partners invests in high-growth, late-stage medical technology companies primarily located in the United States, Europe and Israel. The firm targets medical device companies with innovative technologies that address large unmet clinical needs, aiming to acquire controlling positions in its portfolio companies as the sole or lead investor.

Our portfolio companies gain more than just capital. The firm partners with management teams to accelerate growth and focus on value creation, leveraging longstanding relationships with strategic acquirers, clinical and scientific advisors, regulatory and reimbursement experts and industry executives to support these objectives. Together, we strive to develop technologies and build companies that will significantly advance patient care.

Portfolio Companies

Want to see where InnovaHealth Partners has previously succeeded with medical device companies? Visit our portfolio to learn more.

Blue Belt

Blue Belt is one of three significantly commercialized orthopedic surgical robotics companies. It is now a part of Smith & Nephew.

www.smith-nephew.com/professional/microsites/navio/
OrthoSpace

OrthoSpace offers a minimally invasive, biodegradable balloon that addresses massive rotator cuff tears.

www.orthospace.co.il
OrthoAccel

OrthoAccel is first mover in the pioneering orthodontic treatment acceleration space.

www.acceledent.com/orthodontists/about-us/
BioHorizons

BioHorizons is a global dental implant company with a highly-differentiated technology that prevents soft tissue migration and promotes osseointegration. It is now 60%-owned by Henry Schein.

www.biohorizons.com/
Nexa Orthopedics

Nexa is an orthopedic extremities implant company that develops novel pyrocarbon devices.

Nexa is now a part of Tornier.

Alphatec

Alphatec designs and develops a broad portfolio of spinal implant systems that address the entire spinal fusion procedure.

www.alphatecspine.com

Team

Our firm is led by a team of industry veterans with a strong history of prior success with medical device and technology companies.

Mortimer Berkowitz III

President & CEO

Ariella Golomb, MD

Managing Director

Richard B. Emmitt

Senior Advisor

John McCormick

Managing Director

Lauren Uzdienski

Research Director

IH Interests

Results Published from New InSpace Studies

InSpace reduces pain and improves function in patients with rotator cuff tears.

Read More
Stryker to Acquire Entellus

The $662 million deal expands SYK's ENT presence.

Read More
Device Company CEOs on Innovation and M&A

Our new video series focuses on medical device technology and trends.

Read More
Regentis Enrolls First Patients in IDE Cartilage Trial

The study will compare GelrinC to microfracture.

Read More

Let's Talk